Knowledge Transfer Partnership Sponsored by the Department of Trade & Industry (DTI)

Posted:
4
July 2006

We are pleased to announce that we have launched a unique research project in conjunction with Queen Mary University of London.The Knowledge Transfer Partnership (KTP) sponsored by the Department of Trade and Industry (DTI), and Richmond Pharmacology Ltd is a two year project bringing together academia and commercial expertise.The project will culminate in the development of unique software tools, which will allow for the collection and linking of data from different medical measurement devices into one central repository for analysis.Dr Dilshat Djumanov PhD, a Research Associate from Queen Mary University of London, will undertake this two year research project.Dr Dilshat Djumanov Commented The Knowledge Transfer Partnership gives me the opportunity to undertake a demanding and exciting work based project, in which the results will be implemented in to a commercial environment. Working in conjunction with and having the support from Dr Peter Dabnichki Lecturer in Medical Engineering, Queen Mary University of London, and Dr Radivoj Arezina Research Director, Richmond Pharmacology, this 2 year project will offer Richmond Pharmacology expertise on data acquisition, data processing and software design to compliment and enhance the existing procedures.

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more